ZNRF2 Knockout cell line (SU-DHL-1)

CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.

ZNRF2 (zinc and ring finger 2) encodes a zinc and RING finger protein with ubiquitin protein ligase activity. It participates in regulation of intracellular membrane trafficking and promotes autophagosome-lysosome fusion, a process important for autophagic degradation. ZNRF2 is associated with cytoplasmic vesicle membranes, the plasma membrane, and nuclear compartments and can function as part of protein-containing complexes involved in intracellular membrane organization.

The SU-DHL-1 cell line was established in 1973 from the pleural effusion of a 10-year-old male patient. Originally diagnosed as diffuse histiocytic lymphoma, the tumor was subsequently reclassified as diffuse large cell lymphoma and later as malignant histiocytosis. According to the REAL/WHO classification, the cell line represents anaplastic large cell lymphoma (ALCL) and carries the t(2;5)(p23;q35) translocation resulting in an NPM1-ALK (NPM-ALK) fusion gene. SU-DHL-1 is used as a model for studying ALCL biology and ALK-associated oncogenic signaling.

Before delivery, each clone is authenticated by STR, tested for sterility and mycoplasma, and genotype‑verified by two‑round PCR‑sequencing. Comprehensive QC data accompany every shipment to support reproducible research.